Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,080 | 10-14 weeks | |
50 mg | $1,410 | 10-14 weeks | |
100 mg | $2,250 | 10-14 weeks |
Description | BMS-986120 is a first-in-class oral, reversible protease-activated receptor 4 (PAR4) antagonist with IC50s of 9.5 nM in human blood and 2.1 nM in monkey blood, exhibiting potent and selective antiplatelet effects[1][2]. |
Targets&IC50 | PAR4 (monkey):2.1 nM, PAR4 (human):9.5 nM |
In vitro | BMS-986120 has high binding affinity to PAR4 expressed on HEK293 cells. And it inhibition of PAR4-induced calcium mobilization with an IC50 of 0.56 nM[3]. |
In vivo | BMS, administered at dosages of 0.2, 0.5, and 1 mg/kg, decreases tail withdrawal (TW) by 35±5, 49±4, and 83±4%, respectively. In monkeys, a 1 mg/kg dose of BMS shows no inhibition of platelet aggregation (PA) triggered by PAR1-AP, ADP, and collagen, indicating selectivity. The maximum increases observed in kaolin bleeding time (KBT) and mepacrine bleeding time (MBT) are limited to 2.2-fold and 1.8-fold, respectively[1]. |
Molecular Weight | 513.59 |
Formula | C23H23N5O5S2 |
Cas No. | 1478712-37-6 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.